Intravenous Immunoglobulin Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Takeda, Mitsubishi Tanabe Pharma, AbbVie, Prothya Biosolutions

Posted on
by

Intravenous Immunoglobulin Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Takeda, Mitsubishi Tanabe Pharma, AbbVie, Prothya Biosolutions
The Key Intravenous Immunoglobulin Companies in the market include – Takeda, Mitsubishi Tanabe Pharma, AbbVie, Prothya Biosolutions, and others.

DelveInsight’s “Intravenous Immunoglobulin Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Intravenous Immunoglobulin, historical and forecasted epidemiology as well as the Intravenous Immunoglobulin market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Intravenous Immunoglobulin, offering comprehensive insights into the Intravenous Immunoglobulin revenue trends, prevalence, and treatment landscape. The report delves into key Intravenous Immunoglobulin statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Intravenous Immunoglobulin therapies. Additionally, we cover the landscape of Intravenous Immunoglobulin clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Intravenous Immunoglobulin treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Intravenous Immunoglobulin space.

 

To Know in detail about the Intravenous Immunoglobulin market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Intravenous Immunoglobulin Market Forecast

 

Some of the key facts of the Intravenous Immunoglobulin Market Report:

  • The Intravenous Immunoglobulin (IVIG) market across the 7MM was valued at around USD 7,384 million in 2025 and is expected to expand at a CAGR of 6.9%, reaching approximately USD 13,496 million by 2034 across major markets including the US, EU4, the UK, and Japan.

  • In June 2024, FDA approved YIMMUGOfromGrifols Biotestfor thetreatment of primary immunodeficiencies for 17 and above age group

  • In the Q2 2024 report of Takeda Pharmaceuticals, TAK-880<10% IVIG(Low IgA) filed for registration in the EU in March 2024 and for the USin August 2024 for primary immunodeficiency.

  • Key Intravenous Immunoglobulin Companies: Takeda, Mitsubishi Tanabe Pharma, AbbVie, Prothya Biosolutions, and others

  • Key Intravenous Immunoglobulin Therapies: TAK-880, TA-650, ABBV-383 (Etentami), IVIG-L, and others

  • The Intravenous Immunoglobulin market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Intravenous Immunoglobulin pipeline products will significantly revolutionize the Intravenous Immunoglobulin market dynamics.

  • As per NORD (2024), Guillain-Barré Syndrome (GBS) impacts approximately one to two individuals per 100,000 people annually.

  • According to DelveInsight’s analysis, the total number of prevalent Immune Thrombocytopenia (ITP) cases in the EU4 countries and the UK was approximately 91,900 in 2023.

  • According to DelveInsight’s analysis, the total number of prevalent cases of CIDP in Japan was estimated to be around 2,120 in 2023.

  • According to Duff et al. (2021), more than 6 million individuals globally are impacted by primary immunodeficiencies, yet 70% to 90% of these cases go undiagnosed. Over 430 types of primary immunodeficiencies (PIDs) have been identified, all resulting from inherited abnormalities in various parts of the immune system.

 

Intravenous Immunoglobulin Overview

Intravenous Immunoglobulin (IVIG) is a therapy made from pooled antibodies (immunoglobulins) collected from the plasma of healthy donors. It is administered through a vein to help strengthen the immune system. IVIG is commonly used to treat immune deficiencies, certain autoimmune disorders, and inflammatory diseases. It works by modulating immune responses, reducing inflammation, and neutralizing harmful antibodies in the body.

 

Get a Free sample for the Intravenous Immunoglobulin Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/intravenous-immunoglobulin-market

 

Intravenous Immunoglobulin Epidemiology

The Intravenous Immunoglobulin epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Intravenous Immunoglobulin Epidemiology Segmentation:

The Intravenous Immunoglobulin market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Intravenous Immunoglobulin

  • Prevalent Cases of Intravenous Immunoglobulin by severity

  • Gender-specific Prevalence of Intravenous Immunoglobulin

  • Diagnosed Cases of Episodic and Chronic Intravenous Immunoglobulin

 

Download the report to understand which factors are driving Intravenous Immunoglobulin epidemiology trends @ Intravenous Immunoglobulin Epidemiology Forecast

 

Intravenous Immunoglobulin Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Intravenous Immunoglobulin market or expected to get launched during the study period. The analysis covers Intravenous Immunoglobulin market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Intravenous Immunoglobulin Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Intravenous Immunoglobulin Therapies and Key Companies

  • TAK-880: Takeda

  • TA-650: Mitsubishi Tanabe Pharma

  • ABBV-383 (Etentami): AbbVie

  • IVIG-L: Prothya Biosolutions

 

Discover more about therapies set to grab major Intravenous Immunoglobulin market share @ Intravenous Immunoglobulin Treatment Landscape

 

Intravenous Immunoglobulin Market Drivers

  • Rising prevalence of immunodeficiency disorders

  • Increased use of IVIG in autoimmune and neurological disorders

  • Growing geriatric population

  • Supportive government initiatives and reimbursement policies

  • Increasing awareness and early diagnosis of rare immune disorders

  • Expansion of healthcare infrastructure

 

Intravenous Immunoglobulin Market Barriers

  • High cost of IVIG therapy

  • Supply constraints and plasma shortages

  • Stringent regulatory requirements

  • Limited awareness in underdeveloped regions

  • Competition from alternative therapies

 

Scope of the Intravenous Immunoglobulin Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Intravenous Immunoglobulin Companies: Takeda, Mitsubishi Tanabe Pharma, AbbVie, Prothya Biosolutions, and others

  • Key Intravenous Immunoglobulin Therapies: TAK-880, TA-650, ABBV-383 (Etentami), IVIG-L, and others

  • Intravenous Immunoglobulin Therapeutic Assessment: Intravenous Immunoglobulin current marketed and Intravenous Immunoglobulin emerging therapies

  • Intravenous Immunoglobulin Market Dynamics: Intravenous Immunoglobulin market drivers and Intravenous Immunoglobulin market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Intravenous Immunoglobulin Unmet Needs, KOL’s views, Analyst’s views, Intravenous Immunoglobulin Market Access and Reimbursement

 

To know more about Intravenous Immunoglobulin companies working in the treatment market, visit @ Intravenous Immunoglobulin Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Intravenous Immunoglobulin Market Report Introduction

2. Executive Summary for Intravenous Immunoglobulin

3. SWOT analysis of Intravenous Immunoglobulin

4. Intravenous Immunoglobulin Patient Share (%) Overview at a Glance

5. Intravenous Immunoglobulin Market Overview at a Glance

6. Intravenous Immunoglobulin Disease Background and Overview

7. Intravenous Immunoglobulin Epidemiology and Patient Population

8. Country-Specific Patient Population of Intravenous Immunoglobulin

9. Intravenous Immunoglobulin Current Treatment and Medical Practices

10. Intravenous Immunoglobulin Unmet Needs

11. Intravenous Immunoglobulin Emerging Therapies

12. Intravenous Immunoglobulin Market Outlook

13. Country-Wise Intravenous Immunoglobulin Market Analysis (2020–2034)

14. Intravenous Immunoglobulin Market Access and Reimbursement of Therapies

15. Intravenous Immunoglobulin Market Drivers

16. Intravenous Immunoglobulin Market Barriers

17. Intravenous Immunoglobulin Appendix

18. Intravenous Immunoglobulin Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/